アシュワガンダ由来ウィザフェリンAのヒト癌細胞に対する細胞毒性 : テロメラーゼ発現と非発現細胞の応答に対する分子洞察 by 于 躍 & YU Yue
Cytotoxicity of Ashwagandha Derived Withaferin
A to Human Cancer Cells : Molecular Insights
into the Response of Telomerase Plus and Minus
Cell
著者 于 躍
year 2016
その他のタイトル アシュワガンダ由来ウィザフェリンAのヒト癌細胞
に対する細胞毒性 : テロメラーゼ発現と非発現細
胞の応答に対する分子洞察
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2016
報告番号 12102甲第7945号
URL http://hdl.handle.net/2241/00145396
  
 
 
Cytotoxicity of Ashwagandha Derived Withaferin A to 
Human Cancer Cells: Molecular Insights into the 
Response of Telomerase Plus and Minus Cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
July 2016 
 
 
 
Yue YU 
 
  
 
 
Cytotoxicity of Ashwagandha Derived Withaferin A to 
Human Cancer Cells: Molecular Insights into the 
Response of Telomerase Plus and Minus Cell 
 
 
 
 
A Dissertation Submitted to  
Graduate School of Life and Environmental Sciences,  
University of Tsukuba 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Environmental Studides 
(Doctoral Program in Sustainable Environmental Studies) 
 
 
 
Yue YU 
 
 i 
Abstract 
Cancer is a complex disease, which is regulated by multifaceted network of 
signaling pathways driven by loss of activities of tumor suppressor proteins, gain of 
function of oncogenes and several epigenetic mechanisms. Being different from normal 
cells, cancer cells maintain telomere length to overcome replicative mortality by 
telomerase or alternative lengthening of telomeres (ALT) pathway. Disruption of either 
can induce DNA double-strand break signaling, leading to senescence or apoptosis. 
Significance of microRNAs (miRNAs), small non-coding molecules, has been also 
implicated in a variety of biological processes. miRNA expression correlates with 
various cancers, and these genes are thought to function as both tumour suppressors 
and oncogenes. 
Withania somnifera (Ashwagandha), an important medicinal plant, is commonly 
known as “Indian ginseng” or “winter cherry”. It belongs to Solanaceae family and 
grows in dry regions of South Asia, Central Asia and Africa, particularly in India. It has 
been known to exert anti-tumor activity against various kinds of cancer. However, there 
is few study investigating the telomerase- or ALT-targeted potential of Withaferin-A 
(Wi-A) and the molecular mechanisms regulated by miRNAs. 
Here, we used isogenic cells with or without telomerase and found that Wi-A 
caused stronger cytotoxity to ALT cells. The G2/M arrest and apoptosis resulting from 
Wi-A exposure was specific to ALT cells. Treatment with Wi-A decreased in the 
number of ALT-associated promyelocytic leukemia (PML) nuclear bodies (APBs) (a 
universal characterization of ALT), whereas telomerase activity was unaffected. ALT 
cells treated with Wi-A exhibited severe telomere dysfunction and upregulation of DNA 
damage response. Molecular analysis revealed that treatment with Wi-A lead to Myc- 
mediated transcriptional suppression of MRN complex, which is essential for ALT 
mechanism and cell survival.  
Meanwhile, we recruited arbitrary manipulation of genome and escape from 5-
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Aza-2'-deoxycytidine (5-Aza-dC) induced senescence as a cell based loss-of-function 
screening system. Cells that escaped 5-Aza-dC induced senescence were recovered and 
subjected to miR-microarray analysis with respect to the untreated control. We 
identified miR-335 as one of the upregulated miRs implying that it is normally silenced 
by methylation. In order to characterize the functional significance, we overexpressed 
miR-335 in a variety of human cancer cells, with either telomerase or ALT mechanism, 
and found that it causes growth arrest and hence inhibited incorporation of 5-Aza-dC 
enabling cells to escape induction of senescence. We demonstrate that miR-335 targets 
multiple proteins including p16INK4A, pRB and CARF (Collaborator of ARF) and causes 
growth arrest of cancer cells by complex interactions of its gene targets. Notably, miR-
335 expression is increased by Wi-A treatment in telomerase cells, inducing CARF 
mediated cellular growth arrest. 
Collectively, these results provide novel evidences for the anti-cancer property of 
Wi-A in the aspects of telomere maintenance and miRNA regulation. It provide a new 
strategy for the development of Wi-A based drug screening and designing in the future. 
Keywords: cancer, telomere, cytotoxicity, senescence, microRNA 
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Chapter 1 Introduction 
1.1 Ashwagandha 
Withania somnifera (Ashwagandha, WS), an important medicinal plant, is 
commonly known as “Indian ginseng” or “winter cherry” (Fig.1-1). It belongs to 
Solanaceae family and grows erectly with a normal height of 1.50 m. It is native in dry 
regions of South Asia, Central Asia and Africa, particularly in India. WS is cultivated 
on a commercial scale in India with the production of ~8000 tons (during 2005). The 
annual demand of this herb increased from ~7000 tons (2002) to ~9000 tons (2005).  
For thousands of years, Ashwagandha is used for various kinds of disease 
protection and treatment in Indian traditional Ayurvedic system. It is applied as a 
general tonic that promotes a youthful state of physical and mental health and expands 
happiness. It is in use for a very long time for all age groups and both sexes and even 
during pregnancy without any side effects [1]. The extract is available over the counter 
in the United States as a dietary supplement. It is reported that the root can elevate 
human body’s resilience to stress by improving the cell-mediated immunity [2], and 
helping protect against cellular damage caused by free radicals [3]. The health benefit of 
Ashwaganda is supported by clinical trials in case of anti-inflammatory, anti-stress, 
anti-oxidant, anti-aging, anticonvulsant, anti-hyperglycaemic and anti-carcinogenic 
activities [4]. To date, over 35 chemical constituents have been discovered in WS. 
Among them, alkaloids, steroidal lactones and withanolides are believed to account for 
its extraordinary medicinal properties [5]. 
Withaferin A (Wi-A) is the first member of withanolides to be identified. Later on, 
chemical structure analysis suggests it is characterized by a closed ring consisting of 5 
carbon atoms and a single oxygen atom [6]. Extensive studies indicate Wi-A possess 
inhibitory effect against several types of cancer, which is attributable to (i) induction of 
cell cycle arrest by downregulation of cyclin B1, cyclin A, Cdk2 and p-Cdc2 expression 
and an increase in the levels of p-Chk1 and p-Chk2, (ii) downregulation of expression 
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of HPV E6 and E7 oncoproteins, (iii) induction and accumulation of p53, (iv) increase 
levels of p21WAF1, (v) decrease the levels of STAT3, (vi) increase in p53-mediated 
apoptotic markers-Bcl2, Bax, caspase-3, cleaved PARP and Par-4, (vii) and induced 
COX-2-mediated inflammatory response via miR-25 up-regulation [7-11]. In addition, 
Wi-A also suppresses metastasis via: (i) induction of Vimentin disassembly by ser56 
phosphorylation, (ii) and downregulation of migration-promoting proteins hnRNP-K, 
VEGF, and metalloproteases [12, 13].  
With our gain in knowledge of Wi-A, the therapeutic potential of WA seems very 
promising. However, the pharmacological and toxicological properties for human is 
still elusive. So large scale of pre-clinical studies need to be performed to eliminate any 
side effect in further clinical trials.     
1.2 Telomere, telomerase and ALT 
1.2.1 Telomere structure and function  
Telomeres are long tracts of DNA at the linear chromosome’s ends composed of 
successive TTAGGG repeats that vary in length from 2 to 20 kb [14]. Telomeric DNA is 
double stranded with a single – stranded terminus (G-tail) which is about 130-210 
nucleotides (nt) in human cells. The ends of telomeres form a unique structure called a 
t-loop, which is formed by strand invasion of the 3’ single strand overhang into the 
preceding double stranded telomeric DNA [15, 16]. Despite t-loop, the G-tail is also able 
to form a secondary four-strand structure named Gquadruplexes that can be either 
intermolecular or intramolecular [17]. As a result, such a structure may contribute to 
telomere stability and chromosome-end protection as they prohibit access of nucleases 
and DNA damage response (DDR) detection enzymes.  
A six-protein complex known as “shelterin” has remarkable specificity for 
telomeres. Among of which, TRF1 and TRF2 bind directly to double stranded telomeric 
DNA, while the single-stranded tail is tied up by POT1. Furthermore, TRF2 recruits 
RAP1, and TIN2 can bridge TRF1 and the TRF2/RAP1 complex by binding to both 
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proteins simultaneously with different domains [18, 19]. TRF1 has been shown to promote 
telomere replication, thereby preventing telomeric damage [20]. TRF2 protect telomere 
from loss of 3’ overhang and end to end fusion [21]. POT1 can regulate the telomerase 
essential to balance telomere elongation [22]. A careful analysis measuring the absolute 
and relative amounts of TRF1 and TRF2 in the nucleus revealed that TRF2 is about 
twice as abundant as TRF1 and subcomplexes of shelterin have been detected. 
Quantitation of other shelterin component showed the loading of POT1 is limited by 
the amount of TPP1 [23], suggesting shelterin components, in turn, are regulated by both 
the expression of coding genes and mutual modification that are growing-state specific. 
Moreover, shelterin components also have a key role in suppressing the ATM and ATR 
checkpoint pathways at telomeres. TRF2 can bind to and suppress ATM and POT1 
inhibits ATR. Suppression of TRF2 activity elicits p53 and ATM activation, leading to 
telomere dysfunction induced foci (TIFs) [24, 25]. These considerations may widen our 
understanding of the roles of telomere in chromosome protection and genome integrity. 
In the context of absence of any compensation mechanism, in most somatic cells 
of an adult organism, telomeres shorten during each cell division, resulting in 
cumulative telomere attrition. Consequently, after a finite number of cell divisions, 
telomeres reach a critical length and chromosomes become uncapped, leading to either 
permanent cell cycle arrest or to apoptosis [26-30]. Thus, telomeres act as a “clock” that 
determines lifespan at the cellular level. However, cancer cells are lacking of such 
regulatory mechnism due to the presence of telomerase or alternative lengthening of 
telomeres (ALT). To break the barrier of telomere attrition, about 85-90% cancer cells 
utilize telomerase to synthesizing new telomeric DNA repeats at chromosome ends [31], 
while the remaining 10-15% human cancers lacking detectable telomerase activity 
maintain telomere length by DNA recombination [32]. 
1.2.2 Telomerase 
In most cases, telomerase activity is repressed in somatic cells, with the exception 
of adult stem cells, male sperm cells and renewal tissues [14]. It is, however, a universal 
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characterization of cancer cell lines. The human telomerase is a kind of 
ribonucleoprotein complex enzyme with action of copying the short RNA template 
sequence within the telomerase RNA into DNA. The complex mainly consisted of 
human telomerase reverse transcriptase (hTERT), and an associated template RNA 
called human Telomerase RNA (hTR or hTERC) [33-35]. hTR is ubiquitously expressed 
in all human cells, and telomerase activity is limited by the expression of hTERT, which 
is only found in telomerase positive cells. Introduction of hTERT into telomerase-silent 
cells is sufficient to reactivate telomerase, elongate or maintain telomeres [31, 36]. Besides 
these two core components, many other telomerase-associated proteins, for instance of 
dyskerin, are found and predicted to have an important role in telomerase recruitment, 
stabilization and regulation [37]. 
The distinct difference of telomerase expression between cancer and normal cells 
make telomerase a rational target for cancer therapeutics. Even though the intricacies 
of telomere function have not been fully elucidated, the clinical application of anti-
telomerase therapies for cancer has been making rapid progress in the past 5-10 years. 
GRN163L is one of the first generation of oligonucleotide telomerase inhibitors for the 
treatment of cancer, and has entered Phase I/II clinical trials in patients with chronic 
lymphocytic leukaemia. Ongoing clinical trial results suggest it has the potential to be 
a universal anticancer agent with minimal side effects [38, 39]. In the aspect of gene 
therapy, an oncolytic virus named CG5757 is able to disrupt Rb and hTERT promoter 
region, proceeding to selectively kill the Rb-defective and hTERT-positive cancer cells 
[40-42]. Cells with peptides generated by degradation of hTERT can be recognized and 
killed by cytotoxic T-lymphocytes, which makes telomerase a potential target for 
immunotherapy. Telomerase-based universal cancer vaccines have been subjected to 
clinical trials and showed acceptable safety along with encouraging efficacy on tumor 
inhibition [43-45]. 
1.2.3 Alternative lengthening of telomeres (ALT) 
Differing from telomerase, which uses an RNA template for telomeric DNA 
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synthesis, ALT generates new telomeric DNA from a DNA template via homologous 
recombination (HR). During cell replication, the relatively shorter telomere elongates 
itself by copying DNA sequence from: (i) another existing telomere at adjacent 
chromosome, (ii) another region from the same telomere through t-loop structure, (iii) 
the telomere of sister chromatid [32]. ALT-positive tumor or immortal cells are 
characterized by highly heterogeneous chromosomal telomere lengths; rapid changes 
in telomere length; an abundance of extrachromosomal telomeric DNA in the shape of 
double-stranded telomeric circles (t-circles) and single-stranded circles(C- or G-circles); 
and the presence of ALT-associated promyelocytic leukemia (PML) bodies (APBs) [46-
50]. 
Genetic or epigenetic alterations that unleash ALT are remain unknown, but it has 
been believed that various HR proteins are involved. HR suppressing genes (p53, 
ATRX, DAXX and H3F3A) are found to be associated with ALT activation, and most 
of them affect chromatin remodeling at the telomere [51-54]. Early studies demonstrated 
suppression of HR related components, like MRN complex, SMC5/6 complex and 
BLM helicase, leads to telomere shortening, loss of APBs or alterations of other 
characteristics of ALT cell lines [55]. Compared to other immortalized cells, a large 
proportion of the telomeres in ALT cells evoke a DNA damage response, suggesting a 
high degree of ongoing genomic instability [56]. As a compensation, most of them 
possess a high level of DNA recombination events and defect in G2/M checkpoint [57, 
58]. As a result, cells can keep on proliferating to overcome DNA damage. This dynamic 
process qualified ALT cells for dividing infinitely. 
The MRE11-NBS1-RAD50 complex is the first proteins to be identified as 
necessary for ALT mediated telomere elongation [59]. It seems that this complex plays a 
dual role in telomere biology. Firstly, it functions in the detection and signaling double-
strand breaks (DSB), further recruits ATM to break focis and facilitates 5’ to 3’ resection 
of the DNA ends to create 3’ overhangs for strand invasion [60]. Secondly, the MRN 
complex localizes to telomeres during the S and G2 phases of the cell cycle through 
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direct interaction of NBS1 with TRF2, contributing to G-tail stabilization [61, 62]. 
Furthermore, in telomerase expressing cells, MRN complex may also promote 
accessibility of telomerase to the 3’ end of telomeres via TRF1 inhibition [63].  
ALT has been detected in many tumor types but is most prevalent in tumors of 
mesenchymal origin like glioblastomas, osteosarcomas, soft tissue sarcomas, all of 
which tend to present particularly poor prognosis [64, 65]. Many molecular details of ALT 
remain to be discovered, however, and it is still possible to develop ALT-targeted 
therapeutic approaches for cancer treatment. Recent reports support this notion, as 
repression of ALT in ALT-dependent immortal cell lines resulted in selective 
senescence and cell death, while ALT inhibition by siRNA-targeting of ALT 
components appear to result in more rapid telomere dysfunction [66-68]. 
1.3 microRNAs  
mircoRNAs (miRNAs) are non-coding, single-stranded RNAs of ~22 nucleotides 
and found in both plants and animals [69]. After their initial discovery in a study on 
Caenor-habditis elegans in 1993 [70], the development of research on this small 
sequence is very in the following decade. To date, over 2,500 potential human miRNAs 
are recorded in miRBase, a biological database that acts as an archive of miRNA 
sequences and annotations [71]. The predominant function of miRNAs is to negatively 
regulate the expression of target protein by binding to its coding sequence of messenger 
RNAs (mRNA). Mechanisms of action of miRNAs are mainly recognized in two 
different pathways depending on the level of complementarity between the miRNA and 
the target. First of all, in most of plants, miRNAs have been found to bind with perfect 
complementarity to protein coding mRNA sequences, resulting in mRNA degradation 
through RNA-mediated interference (RNAi) pathway [72, 73]. Nevertheless, vertebrate 
miRNAs are believed to use the other mechanism. Instead of the cleavage of their 
mRNA targets, these miRNAs inhibit target gene expression in post-transcription level 
by imperfect match to the 3’ untranslated regions (UTRs) of target mRNA sequence [74-
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76]. In this case, the protein level of target genes is reduced, but mRNA level is barely 
affected. About one-third of human mRNAs are potentially controlled by miRNAs, 
because of the short microRNA–mRNA binding site which is commonly 6–8 base pairs. 
Each microRNA has the potential to target multiple different mRNAs, while a single 
mRNA may also have target sites for multiple microRNAs. 
1.3.1 microRNAs biogenesis 
The general biogenesis of miRNAs has already been elucidated. First, 
miRNA coding gene is transcribed by RNA polymerase II, generating long 
primary transcripts (pri-miRNAs). Subsequently, the RNase III–type 
enzyme (Drosha) processes the long primary transcripts into ~70-
nucleotide hairpin precursors (pre-miRNA). The pre-miRNAs are then 
exported into the cytoplasm and undergo an additional processing step in 
which a double- stranded RNA of ~22 nucleotides duplex structures in 
length. Next, the less stable of the two strands in the duplex is incorporated 
into the miRNA-induced silencing complex (miRISC). The mature miRNA 
strand is preferentially retained in the functional miRISC complex and 
negatively regulates its target genes [77-81]. 
1.3.2 miroRNAs and cancer  
miRNA expression correlates with various cancers, and these genes are thought to 
function as both tumor suppressors and oncogenes. The first indication of a link 
between microRNA deregulation and cancer has been uncovered in 2002. In this study, 
they found that B-cell chronic lymphocytic leukemia (CLL) often have deletions or 
downregulation of two clustered miRNA genes, mir-15a and mir-16-1 [82]. After this 
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first study a great number of microRNAs have been found deregulated in cancer. For 
example, mature miRNA levels of miR-143 and miR-145 are significantly reduced in 
colorectal tumors [83]. Another research indicated that miR-21 is 5-100-fold up-
regulated in glioblastoma than normal tissue and knockdown of this miRNA in 
glioblastoma cell lines lead to apoptosis, which implies an oncogenic role for it [84]. 
miRNA-induced abnormal regulatory mechanisms are implicated in the 
pathogenesis of malignant tumors. Considering that loss of functional p53 is one of the 
most represented genetic abnormalities in cancer, the association of p53 and miRNA 
has been widely investigated. Accumulative studies revealed that [85]: (i) p53 promotes 
the Drosha-mediated processing and maturation of certain miRNAs with growth-
suppressive function, including miR-16-1, miR-143 and miR-145. (ii)The transcription 
expression of numbers of miRNAs, including miR-34a/b/c, miR-145, miR-107, miR-
192 and miR-215, are induced by p53. (iii) Some miRNAs are able to negatively 
regulate p53 function by direct binding to 3’UTR in mRNA, or positively regulate 
molecular antagonists of p53, like HDM2. 
The differential expression of certain miRNAs has already been shown to be an 
accurate predictor of a patient’s overall prognosis. Importantly, cancer-associated 
microRNA biomarkers can be detected in biological fluids, such as blood, urine and 
saliva, allowing less-invasive monitoring [86]. Isolation of exosomes from serum 
showed that a signature involving two microRNAs and one small non-coding RNA can 
be used for non-invasive diagnosis of glioblastoma [87]. The first microRNA-based 
therapy on clinical trial is MRX34: a synthetic miR-34a mimic loaded in liposomal 
nanoparticles. miR-34 inhibits multiple oncogenic pathways as well as stimulates anti-
tumor immune response to induce cancer cell death. Introducing a mimic of miR-34 
into cancer cell lines derived from patients with liver, lung, colon, pancreatic and breast 
cancers results in significant reductions in cell proliferation. Lipid-based local and 
systemic delivery of miR-34a in animal studies has also shown positive results for lung 
cancer [88-90]. 
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Study on miRNAs provides us insight into the underlying mechanisms of 
oncogenesis, and offers a promising opportunity for cancer detection, diagnosis, and 
prognosis assessment. 
1.4 Innovative point and structure of the thesis 
This experimental study provided novel evidences for the anti-cancer property of 
Wi-A in the aspects of telomere maintenance and miRNA regulation. It indicated a new 
strategy for the development of Wi-A based drug screening and designing in the future 
Chapter 1 Introduction 
In this chapter, the background of this research was introduced, including 
Ashwagandha, telomerase, ALT and miRNA. Motivation and the structure of this study 
were also addressed.  
Chapter 2 Withaferin-A exhibits stronger cytotoxicity to telomerase minus ALT 
cancer cells 
In this chapter, Wi-A-induced phenotype(s) in TEP and ALT cells was clarified. A 
set of experiments were applied for exploring the underlying mechanism. 
Chapter 3 Noncoding regulation of drug induced DNA damage signaling and 
cellular senescence in ALT cells 
 In this chapter, miR-335 was screened out. Its functional characterization and 
effect of Wi-A on miR-335 regulation were discussed as well. 
Chapter 4 Conclusions and future researches 
In this chapter, the main results are summarized. In particular, the future research 
points was also directed.  
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Fig. 1- 1 Ashwagandha plant 
https://www.strictlymedicinalseeds.com/product.asp?specific=2784# 
http://www.plantoftheweek.org/week194.shtml 
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Fig. 1- 2 Schematic representation of telomere structure [91] 
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Fig. 1- 3 Model of microRNAs biogenesis [92] 
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Chapter 2 Withaferin-A exhibits stronger cytotoxicity to 
telomerase minus ALT cancer cells 
2.1 Introduction 
Normal somatic cells have a finite life span and undergo a permanent growth arrest 
called cellular senescence that acts as a strong tumor suppressor mechanism. It is 
regulated by telomere (chromosomal ends with tandem repeats of TTAGGG sequence) 
-shortening (an inherit DNA replication problem), and activity of tumor suppressor 
genes [93, 94]. While these characteristics of normal cells have been established as 
hallmarks of senescence, telomere length maintenance is essential for cellular 
immortalization, and carcinogenesis [95]. Cancer cells circumvent telomere shortening 
by activation of telomerase, a ribonucleoprotein consisting of RNA (TR) and reverse 
transcriptase enzyme (TERT) component that adds TTAGGG to telomeric ends and 
offsets the progressive loss of telomeres [96]. Ectopic expression of hTERT in normal 
human fibroblasts has been shown to induce elongation of telomeres, permanent cell 
proliferation and susceptibility to experimental transformation [97, 98]. In contrast to the 
large majority of cancer cells that maintain their telomeres by upregulation of 
telomerase, telomerase-negative cancer cells maintain their telomeres by mechanisms 
referred to as ALT (Alternate Lengthening of Telomeres). ALT cells are characterized 
by very heterogeneous telomeres and possess large donut-shaped nuclear structures 
(ALT-associated Promyelocytic Leukemia (PML) Body) called APB that contain 
telomeric DNA and several proteins including PML, TRF1, TRF2, Replication factor 
A, RAD51, RAD52 [47, 62, 99-102]. Reconstitution of telomerase activity in ALT cells has 
revealed that human cells are capable of utilizing telomerase- dependent and -
independent mechanisms of telomere maintenance concomitantly [103, 104]. ALT has 
been detected not only in cultured cancer cells but also in the tumor tissues accounting 
for 10-15% of all cancers with high occurrence in astrocytomas and sarcomas [105-108]. 
The MRE11-RAD50-NBS1 (MRN) protein complex acts as a DNA damage 
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sensor and regulates signaling involved in DNA repair, cell cycle regulation, telomere 
maintenance and genome stability [109]. It regulates a number of kinases, like ATM 
(ataxia-telangiectasia mutated), ATR (ataxia-telangiectasia and Rad-3-related), and 
DNA PKcs (DNA protein kinase catalytic subunit) that control DNA damage-repair 
signaling and survival/growth arrest/apoptosis of cells in response to DNA damage [110-
112]. MRN is essential for timely activation of ATM-mediated pathways [113]. The 
dysfunction of MRN elements has been associated with genome instability disorders 
including ataxia telangiectasia (A-T), A-T-like disorder (ATLD) and Nijmegen 
breakage syndrome (NBS1). The latter is an autosomal genetic disease leading to 
premature aging, rapid telomere shortening, increased cancer incidence, chromosome 
instability, and sensitivity to ionizing radiation [114]. NBS1 plays a critical role in DNA 
damage response and the preservation of chromosomal integrity [115]. Whereas 
overexpression of NBS1 was shown to increase cell proliferation [116], its knockdown 
led to hypermutability and telomere changes that have been related to cancer 
predisposition in NBS disease [117]. Hypomorphic mutations MRE11 gene lead to A-T 
like disease (A-TLD) [118]. Cells compromised for Rad50 also showed rapid shortening 
of chromosome ends and their fusions [119, 120]. siRNA-mediated depletion of any of the 
subunits of MRN complex led to ablation of other subunits of the complex suggesting 
their co-regulation [59, 121, 122]. Overexpression of Sp100 that held the MRE11, RAD50, 
and NBS1 proteins away from APBs resulted in repression of the ALT mechanism 
including telomere length changes, and suppression of APB formation [55] suggesting 
that MRN is involved in ALT mechanism(s) of telomere maintenance.  
It has been shown that MYCN transcriptionally control the expression of each 
component of the MRN complex that is required for MYCN-dependent proliferation 
[123]. c-Myc was shown to directly activate NBS1 and its function in DSB repair 
pathway [116]. c-Myc overexpression caused telomerase reactivation and telomere 
stabilization leading to continued proliferation of cells [97]. These results indicated that 
NBS1 is a direct transcriptional target of c-Myc and links the function of c-Myc to the 
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regulation of DNA-DSB repair pathway [116]. Consistent with the telomerase activation 
in cancer, anti-telomerase drugs are trusted as potent anti-cancer therapeutics. However, 
ALT tumors would be refractory to these drugs and hence urge the need of identification 
and characterization of new anti-ALT drugs.   
In this study, we used unique isogenic cells with/without telomerase and 
investigated the anticancer potential role of Wi-A on telomere maintenance mechanism. 
2.2 Materials and methods 
2.2.1 Preparation of Withaferin A 
Withaferin A (Wi-A) was prepared from the dried Ashwagandha leaves, as 
described previously [124]. Integrity of the preparation was determined by HPLC and 
NMR analysis as described [124]. Stock of Wi-A (10 mM) were prepared in DMSO and 
stored in -20℃. Working concentrations of Wi-A were prepared in cell culture medium. 
2.2.2 Cell culture, treatments and viability assays 
Human normal fibroblasts (MRC5), breast carcinoma (MCF7) and melanoma 
(G361) were obtained from Japanese Collection of Research Bioresources (JCRB, 
Japan). SV40-immortalized human fibroblast lines (JFCF-6/T.1J/6B and JFCF-
6/T.1J/6G (telomerase), JFCF-6/T.1L and JFCF-6/T.1J/1-4D (ALT)) were generated in 
the laboratory of Dr. Reddel. All the four cell lines were subclones from the same 
transformation event as described earlier [125-127]. MRC5-hTERT was a kind gift from 
Dr. Reddel as well. Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10%(v/v) fetal 
bovine serum (Gibco BRL), and 1%(v/v) penicillin/streptomycin in the presence of 5% 
CO2 at 37℃. Cells were treated with Wi-A at about 60% confluency. Morphological 
observations were recorded by phase contrast microscope (Nikon Eclipse TE300, 
Japan). The plates were stained with Crystal Violet and scanned for records. Cell 
viability was determined by MTT assay (Life technologies, Carlsbad, CA, USA) 
following manufacturer’s instructions. Briefly, cells after the treatment with Wi-A for 
 16 
24-48 h were incubated with MTT (0.5 mg/mL) for 4 h at 37℃  followed by 
replacement of MTT containing medium with 100 μl DMSO to dissolve formazan 
crystals. Plates were then read on a microplate reader (infinite M200 PRO, TECAN, 
Switzerland) at 570 nm. For long-term cell viability and proliferation, colony-forming 
assay was performed. 500 cells were plated in a 6-well plate and treated with Wi-A for 
6 h. Then cells were left to form colonies for the next 10-15 days with a regular change 
of medium on every third day.  Colonies were fixed with pre-chilled methanol/acetone 
(1/1, v/v) 10 min on ice, stained with 0.1% crystal violet solution, photographed and 
counted. 
2.2.3 Antibodies 
The following antibodies were used in this study: rabbit anti-PARP-1(H-250), anti-
caspase-3(H-277) and anti-POT1(H-200) (Santa Cruz, CA, USA); goat anti-PML(N-
19) (Santa Cruz); mouse anti-p53(DO-1), anti-Cyclin B1(GNS1), anti-N-myc and anti-
TRF2(4A794) (Santa Cruz); rabbit anti-c-Myc(Y69) anti-PARP-9 and anti-
PML(Abcam, Cambridge, MA, USA); mouse anti-Rad50(13B3/2C6), anti-
Mre11(12D7) and anti-NBS1(NBS1-501) (Abcam); rabbit anti-phospho-histone 
H2A.X(20E3) and anti-Rad50(Cell Signaling, MA, USA); Mouse anti-TRF2(Cell 
Signaling); mouse anti-phospho-histone H2A.X(Millipore, Billerica, MA, USA); and 
rabbit anti-NBS1(Novus, Cambridge, UK). Anti-beta Actin antibody (AC-15) (Abcam) 
was used as an internal loading control. 
2.2.4 Flow cytometry analysis 
For the cell cycle analysis, cells were harvested by trypsin. Cell pellets were 
washed with cold PBS followed by addition of cold 70% ethanol drop-wise and 
incubated at at 4℃ overnight. The fixed cells were centrifuged at 800g for 5 min at 
4℃, washed with cold PBS twice and then re-suspended in 0.25 ml PBS. The cells 
suspensions were treated with RNase A at 37℃  for 1 hour followed by brief 
centrifugation to discard supernatant. Cells were re-suspended in 200 µl of Cell Cycle 
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Guava reagent (Millipore, Billerica, MA, USA), incubated for 30 min in dark, and 
analyzed by EasyCyte Guava cytometer (Millipore). The data were further analyzed 
using FlowJo software (version 7.6, Flow Jo, LLC., USA). 
For detection of apoptosis, WA treated attached and suspended cells were collected. 
Cells were suspended in 100 μl of medium and incubated together with 100 μl of Guava 
Nexin Reagent, a pre-made cocktail containing Annexin V-PE and 7-AAD, in a final 
volume of 200 μl and incubated for 20 minutes at room temperature in the dark. 
Samples then were measured on EasyCyte Guava cytometer (Millipore) and analyzed 
using FlowJo software. 
2.2.5 Luciferase reporter assay 
PG13-luc (wt p53 binding sites) was a gift from Bert Vogelstein (Addgene plasmid 
# 16442). Cells were cultured in 6-well plate, co-transfected with 1 μg of luciferase 
constructs (PG13-luc) and 100 ng of control vector oligonucleotide (pRL-TK using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 24-48 h, luciferase activity 
was measured using a dual luciferase reporter assay system (Promega, Madison, WI, 
USA) following the manufacturer’s protocol. Experiments were carried out in triplicate 
and repeated at least three times. 
2.2.6 Comet assay 
DNA double-strand breaks were quantitated by a Comet assay system (Trevigen, 
Inc, Gaithersburg, MD, USA) according to the manufacturer’s recommendations. 
Briefly, JFCF-6B and JFCF-1L cells were treated with or without WA for 24 h before 
mixing with low-melting point agarose and applied onto the CometSlide (Trevigen). 
Cells on the slides were lysed with prechilled lysis solution and incubated with neutral 
unwinding solution. Samples were then subjected to electrophoresis in cold neutral 
electrophoresis solution at 21 V for 30 min. Slides were washed twice with water and 
70% ethanol and air dried before the addition of Gel Green solution (Biotium, Hayward, 
CA, USA). At least 200 cells on each slide were randomly selected for analysis using 
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Carl Zeiss microscope (Axiovert 200 M, Tokyo, Japan) with epifluorescence optics. 
The extent of DNA damage was calculated and showed as percent DNA in the tail using 
the OpenComet (v1.3), a plugin for the image processing program ImageJ. The study 
was repeated independently three times. The data are displayed as a box and whisker 
diagram showing median and middle quartiles with whiskers at the min and max. 
2.2.7 Immunofluorescence 
Cells were plated on a glass coverslip placed in a 12-well culture dish. After 24 h, 
when cells had attached well to the dish, they were washed with cold PBS and fixed 
with pre-chilled methanol/acetone (1/1, v/v) mixture or 4% paraformaldehyde for 10 
min. Fixed cells were washed with PBS, permeabilized with 0.5% Triton X-100 in PBS 
for 10 min and blocked with 0.2% BSA/PBS for 1 h. Cells were incubated with 
appropriate antibody described above at 4°C overnight, washed thrice with 0.2% Triton 
X-100 in PBS, and then incubated with Alexa-594/488-conjugated goat anti-mouse or 
anti-rabbit (Molecular Probes, Invitrogen) secondary antibodies. Finally cells were 
counterstained with or without Hoechst 33342 (Sigma) for 10 min in dark. After 
extensive washings with 0.2% Triton X-100 in PBS, cells were mounted and stored at 
4°C for microscope analysis. 
The Telomere dysfunction induced foci (TIF) assay based on the co-localization 
detection of DNA damage markers (ɣH2AX) and telomeric protein (TRF1 or TRF2) 
was performed as described [128]. APBs detection (double staining of telomere shelterin 
proteins, such as TRF2 and APB-associated protein such as PML) was performed as 
described [125]. Stained samples were examined on a Zeiss Axiovert 200M microscope 
and analyzed by AxioVision 4.6 software (Carl Zeiss). At least 200 cells (on duplicate 
slides) were evaluated for each treatment condition for co-localization foci counting. 
Images were quantified by ImageJ software (National Institute of Health, Bethesda, 
MD). 
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2.2.8 Western Blotting 
Cells were lysed with radioimmunoprecipitation assay buffer (Thermo Scientific) 
containing complete protease inhibitor cocktail (Roche Applied Science, Mannheim, 
Germany). Cell lysates were separated on a SDS-polyacrylamide gel and transferred 
onto PVDF membranes. After probing with the primary antibody as indicated, the blots 
were incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit 
antibodies (Santa Cruz) and detected using ECL substrate (Amersham Pharmacia 
Biotech/GE Healthcare, Piscataway, NJ, USA). Densitometric quantitation of the 
representative immunoblots was carried out using the ImageJ software (National 
Institute of Health). All the experiments were performed in triplicate at least three times. 
2.2.9 RNA extraction and real-time qRT–PCR 
Total RNA was isolated from cells using the RNeasy mini kit (Qiagen, Standford 
Valencia,CA, USA). The concentration and purity of RNA were determined by 
ultraviolet spectrophotometry (A260/A280 >1.9) using NanoDrop ND-1000 
(Nanodrop Technologies, Wilmington, DE, USA). Equal amount of RNA were used for 
reverse transcription following the protocol of QuantiTect Rev. Transcription Kit 
(Qiagen). The real-time qRT–PCR was performed using SYBR® Select Master Mix 
(Applied Biosystems). The qPCR oligonucleotide primers sets were described as follow: 
NBS1 sense (5’-aagaagatacatgggatttgagtg-3’), NBS1 antisense (5’-
tggagactttgatttgatttcttttggc-3’); MRE11 sense (5’-gccttcccgaaatgtcacta-3’), MRE11 
antisense (5’-ttcaaaatcaacccctttcg-3’); RAD50 sense (5’-gaattatccactgaagttcagt-3’), 
RAD50 antisense (5’-tccaaagggcttacctgctc-3’); 18S sense (5’-cagggttcgattccgtagag-3’), 
18S antisense (5’-cctccagtggatcctcgtta-3’). qRT-PCR reaction was carried out in 
triplicate on the Eco™ real time system (Illumina, San Diego, CA USA). The results 
were analyzed and expressed as relative expression of threshold cycle value, which was 
then converted to x-fold changes (2 − △△Ct). 
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2.2.10 TRAP assay 
Telomerase activity was determined with a PCR-based telomeric repeat 
amplification protocol (TRAP) enzyme-linked immunosorbent assay (ELISA) kit 
(Roche, Mannheim, Germany) according to the manufacturer's protocol. In brief, cells 
were collected 24/48 h after treatment. The cells were washed three times with cold 
PBS, homogenized in 200 μl cell lysis buffer, and incubated on ice for 30 min. For the 
TRAP reaction, 10 μg of cell extract was added to 25 μl of reaction mixture, and sterile 
water was added to a final volume of 50 μl. PCR was then performed as follows: primer 
elongation (30min, 25°C), telomerase inactivation (5 min, 94°C), product amplification 
for 30 cycles (94°C for 30 sec, 50°C for 30 sec, and 72°C for 90 sec) and then balance 
(10 min at 72°C). A total of 5 μl of PCR products was added to a streptavidin-coated 
96-well plate and hybridized to a digoxigenin (DIG)-labeled telomeric repeat-specific 
detection probe. The immobilized PCR products were detected with peroxidise-
conjugated anti-DIG antibody. After addition of the stop reagent, the plate was assessed 
with a plate reader at a wavelength of 450 nm within 30 min. 
2.2.11 Statistical analysis 
All experiments were carried out in triplicates, and data were expressed as mean 
± standard deviation (SD). Two-tailed Student’s t-test or nonparametric ManneWhitney 
U-test, whichever was applicable, was used to determine the degree of significance 
between the control and experimental sample. Statistical significance was defined as p-
value ≤ 0.05. 
2.3 Results and discussion 
2.3.1 Withaferin A causes stronger cytotoxicity to ALT cells 
We used isogenic cells with and without telomerase for cytotoxicity assays in 
response to Withaferin-A. As shown in Figs. 2-1A - 1C, dose-dependent cytotoxic 
response was observed for all the four cell lines (Telomerase Plus-TEP and telomerase 
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negative, ALT). Of note, ALT (JFCF-1L and 4D) cells showed stronger cytotoxicity at 
all doses as compared to the Telomerase Plus (TEP; JFCF-6B and 6G) cells. The IC50 
values for 24h treatment were 0.6 μg/ml (JFCF-4D) and 0.9μg/ml (JFCF-1L) for ALT, 
and 1.2 μg/ml (JFCF-6B) and 1.4 μg/ml (JFCF-6G) for TEP cells. For 48 h treatment, 
IC50 values were 0.19 μg/ml (JFCF-4D), 0.25 μg/ml (JFCF-1L) for ALT, and 0.44 μg/ml 
(JFCF-6B) and 0.5 μg/ml (JFCF-6G) for TEP cells. The results were confirmed by 
visual observations that showed that whereas ALT cells underwent apoptosis at 0.5 and 
1 ug/ml Wi-A, TEP cells were not affected (Fig. 2-2A). In line with these observations, 
long–term survival (colony forming assays) with low doses (0.25 μg/ml) of Wi-A 
showed that Wi-A caused stronger cytotoxicity to ALT cells as compared to the TEP 
cells (Fig. 2-2B). 
2.3.2 Withaferin A caused stronger G2-M arrest and apoptosis of ALT cells 
Anti-proliferative effect of many natural chemotherapeutic agents is highly related 
to their ability to cause growth arrest or apoptosis [11, 129-132]. To determine whether 
cytotoxicity of Wi-A to ALT and TEP cells was due to the induction of growth 
arrest/apoptosis, we next performed cell cycle analysis on control and Wi-A treated 
cells. As shown in Figs. 2-3A and 3B, Wi-A treated ALT cells showed significant 
increase in the number of cells in G2/M phase. Of note, equivalent doses did not cause 
similar G2/M arrest in TEP cells. Furthermore, the treatment with Wi-A led to dramatic 
induction of apoptosis in ALT (JFCF-1L), but not in TEP (JFCF-6B) cells (Figs. 2-4A 
and 4B).  
In order to get molecular insights to the apoptotic phenotype induced by Wi-A, we 
examined the expression level of pivotal proteins associated with apoptosis and G2/M 
transition by Western Blotting. As shown in Figs. 2-5A and 5B, we found that, in the 
ALT cells, Wi-A treatment caused a marked increase in the cleaved PAPR-1 and PARP-
9 (established makers of apoptosis). Consistent with this, total PARP-1/9 showed 
decrease in Wi-A treated ALT cells. In contrast, no significant change was observed in 
Wi-A treated TEP (JFCF-6B) cells. Similar to the change in PARP-1/9 that endorsed 
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occurrence of apoptosis in Wi-A treated ALT cells, procaspase-3 showed decrease in 
ALT, but not in TEP cells treated with equivalent dose (0.5 μg/ml) of Wi-A (Fig. 2-5C).  
We next examined p53 and Cyclin B1, the two key regulators of cell cycle 
progression. As shown Fig. 2-6A, both ALT (JFCF-1L) and TEP (JFCF-6B) cells did 
not show wild type p53 activity as determined by wild type p53-dependent reporter 
assay. Western blotting for p53 in control and Wi-A treated cells revealed its down-
regulation in ALT cells; TEP plus cells did not show such decrease in mutant p53 (Fig. 
2-6B). Similar to the effect of Wi-A on p53, Cyclin B1 showed decrease in Wi-A treated 
ALT cells only. TEP cells, on the other hand, showed small/moderate increase in Cyclin 
B1 (Fig. 2-6B). Taken together, these data suggested that stronger toxicity of Wi-A to 
ALT cells is mediated by induction of apoptotic signaling. 
2.3.3 Withaferin A causes the phenotype inhibition of ALT, but not that of telomerase 
Given the above findings that Wi-A caused stronger cytotoxicity to ALT cells, we 
investigated the possibility of the effect of Wi-A on ALT mechanism involved in 
immortalization process of these cells. We examined a well-established marker (APBs 
formation) of ALT cells by visualizing co-localization of TRF2 (telomeric binding 
protein) and PML bodies. As shown in Fig. 2-7A, we detected APBs selectively in ALT 
cells. Of note, Wi-A treated ALT cells showed reduction in APBs by 20-40 % reduction 
in several independent experiments (Fig. 2-7B). To test the effect of Wi-A on telomerase 
activity, we performed TRAP assay in TEP (JFCF-6B, MCF7 and G361) cells. However, 
Wi-A treated TEP cells did not show any inhibition of telomerase activity (Fig. 2-8A). 
In order to further rule out the effect of Wi-A on telomerase, we used normal human 
fibroblasts (MRC5) and their hTERT-derivatives. As shown in Fig. 2-8B, these cells 
showed similar response to Wi-A suggesting that telomerase is not a direct target of Wi-
A cytotoxicity to TEP cells. Taken together, Wi-A caused inhibition of ALT mechanism 
and hence caused stronger cytotoxicity to ALT cells. 
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2.3.4 Withaferin A causes stronger upregulation of DNA damage response in ALT cells 
We next performed neutral Comet assay for measuring DNA double strand breaks 
(DSB) directly. As the data shown in Fig. 2-9A and 9B, a marked (2-fold) increase in 
DSB formation was observed in ALT cells exposed to Wi-A. On the other hand, DNA 
percent in tail of Wi-A treated TEP (JFCF-6B) cells showed no difference with respect 
to the control group suggesting that these cells are somewhat resistant to Wi-A induced 
DSB. The induction of DNA breaks after Wi-A treatment was also assayed by ɣH2AX 
immunostaining. Whereas JFCF-6B cells showed no difference in ɣH2AX staining 
between control and Wi-A (0.25 ug/ml) treated cells, JFCF-1L cells showed large 
increase in the number of ɣH2AX positive cells (Fig. 2-9A and 9C). These data were 
consistent with Comet assay data showed above and suggested that Wi-A caused 
stronger DNA Damage response in ALT cells. 
To ascertain whether Wi-A treatment lead to telomere de-protection, we measured 
the number of cells with telomere-dysfunction-induced foci (TIF) by co-localization of 
ɣH2AX and TRF2 signals in control and Wi-A treated (Fig. 2-10A). We found that Wi-
A increased the number of TIF-positive cells (TIFs ≥4) from ~10% up to ~25% in ALT 
(JFCF-1L) cells (Fig. 2-10B). In contrast to the induction of telomere damage by Wi-A 
in ALT cells, TEP (JFCF-6B) cells showed no significant difference in telomeric DNA 
damage under the same conditions (Fig. 2-10A and 10B).  
Several studies have provided evidence that telomere binding proteins TRF2 and 
POT1 are predominantly involved in chromosome end protection by preventing DNA 
damage activation [133] [134]. In view of these reports and our above findings, we 
considered whether Wi-A targets TRF2 and POT1. Western blots for these proteins 
revealed down-regulation of both TRF2 and POT1 in Wi-A treated ALT cells; TEP cells 
showed lower level of expression that was not altered by Wi-A treatment (Fig. 2-11A 
and 11B). These data suggested that stronger cytotoxicity of Wi-A to ALT cells is due 
to, at least in part, its effect on ALT mechanism enriched in these cells. 
 24 
2.3.5 MRN complex is involved in Wi-A caused DNA damage 
Based on the above data that suggested targeting of ALT mechanism by Wi-A, we 
investigated MRN complex proteins that are essential for ALT mechanism and APB 
assembly [59, 135]. Western blotting with specific antibodies in control and Wi-A treated 
cells revealed a sharp decrease of NBS1 and MRE11 and relative less reduction of 
RAD50 in the latter (Fig. 2-12A and 12C). TEP cells showed only a small/negligible 
change (Fig. 2-12A and 12C). We also performed real-time PCR for their transcripts 
and found reduction in NBS1, but not in MRE11 and RAD50 in ALT cells. Rather, a 
slight increase was observed in MRE11 and RAD50 in Wi-A treated cells. TEP cells 
also showed a small increase in RAD50 (Fig. 2-12B). Since MRN complex is regulated 
by n-myc and c-myc [116], we next performed Western blotting for myc proteins 
expression in control and Wi-A treated ALT and TEP cells. Of note, Wi-A led to 
significant decrease of both in JFCF-1L, while myc expressions in JFCF-6B treated 
cells were barely changed (Fig. 2-12A). Consequently, we concluded that Wi-A caused 
down-regulation of MRN complex proteins in ALT cells through the inhibition of their 
transcriptional factor n-myc/c-myc. 
DNA damage is an inherit phenomenon that occurs with DNA replication and 
several other functions of cells that are essential for cell survival. Cells possess built-in 
DNA damage sensing and repair mechanisms constituted of MRN-ATM/ATR-p53-p21 
signaling [113, 118, 136]. Telomere shortening has been established to evoke DNA damage 
response that initiates senescence and apoptosis to avoid tumorigenesis [98]. Cancer cells 
escape from telomere shortening by mechanism(s) involving either telomerase or ALT 
[137]. Both of these have been considered as drug targets for cancer therapy. More efforts 
have been focused on the telomerase inhibitors due to high incidence (80-90%) of 
telomerase activation as compared to (10-20%). The presence of ALT is more common 
and associated with decreased clinical outcome than telomerase mechanism in 
astrocytomas and glioblastomas and fibrous histiocytomas, liposarcomas. Hence, the 
drugs effective for ALT cells are important and valuable for cancer treatment. Recently, 
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an ATR inhibitor, VE-821 was shown to cause ALT stronger DNA damage to ALT 
cancer cells [138]. In vitro studies have demonstrated that telomerase and ALT 
mechanism can co-exist within individual cell. Inhibition of TEP could activate ALT or 
vice versa [139] raising the need for dual action inhibitors. Wi-A could serve as one of 
such promising candidate drug.  
2.4 Summary 
We found that Wi-A caused stronger cytotoxity to ALT cells. It was associated 
with ALT-associated promyelocytic leukemia (PML) nuclear bodies (APBs), an 
established marker of ALT. Comparative analyses of telomerase positive and ALT cells 
revealed that Wi-A caused stronger telomere dysfunction and upregulation of DNA 
damage response in ALT cells. Molecular analyses revealed that the treatment with Wi-
A lead to c-Myc- and n-Myc-mediated transcriptional suppression of MRN complex, 
an essential component of ALT mechanism. The results suggest that Wi-A may be a 
new candidate drug for ALT cancers. 
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Fig. 2- 1 MTT assay (A and B) and Crystal violet staining (B) showed Withafein A 
exhibit stronger cytotoxicity to ALT cells, comparing to TEP cells. 
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Fig. 2- 2 Effect of Withaferin A on the morphological changes (A) in JFCF-6B (TEP) 
and JFCF-1L (ALT) cells. Withaferin A show cytotoxicity to JFCF-1L even in low dose. 
Long-term colony forming assay (B) showed Wi-A treatment result in about 20% and 
40% reduction in JFCF-6B and JFCF-1L cells, respectively. 
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Fig. 2- 3 Cell cycle analysis (A) of control and Withafein A treated cells is shown. 
Withafein A led to significant G2/M arrest in JFCF-1L but not in JFCF-6B. Quantitation 
of cell cycle distribution data (B) obtained from three independent experiments.  
 
 
 
Control 
J
F
C
F
-6
B
 
Wi-A 0.25 μg/ml 
J
F
C
F
-1
L
 
0
20
40
60
80
100
120
Ctrl Wi-A Ctrl Wi-A
JFCF-6B JFCF-1L
%
 o
f 
c
e
ll
 p
o
p
u
la
ti
o
n
G0/G1 S G2/M
A 
B 
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2- 4 Withaferin A induced apoptosis in JFCF-1L(ALT) cell. Cells were treated with 
Withaferin A (0.25 μg/ml) for 24h, and apoptosis was analyzed by staining 
phosphatidylserine translocation with Annexin V/7-ADD. Annexin V positive (early 
and late apoptosis) cells were considered as the apoptotic population (A). Quantitation 
of apoptotic cells from three independent experiments is shown in B. 
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Fig. 2- 5 Western blotting analysis of apoptosis-associated proteins. An increase in 
cleaved PARP-1/9 (A and B) and decrease in procaspase-3 (C) were observed in JFCF-
1L (ALT) cells in response to Withaferin A treatment. Quantitation results were 
represented as mean ± SD of three independent experiments. 
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Fig. 2- 6 p53 promoter reporter assay showed JFCF series cells possess mutant type 
p53. U2OS served as positive control (A). p53 and cyclin B1 were evaluated by Western 
blotting in Withaferin A-treated JFCF cells with densitometric quantitation of 
representative blots from at least three independent experiments (B). 
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Fig. 2- 7 Double immunostaining of PML and TRF2 (A) showed a decreased number 
of APBs in JFCF-1L(ATL) cells after Withaferin A treatment. The number of APBs per 
cell was measured by colocalization of PML and TRF2 signals. 200 Cells with at least 
3 signals were counted. Quantitation results were represented as mean ± SD of three 
independent experiments. Scale bar = 5 μm. 
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Fig. 2- 8 Effect of Withaferin A on telomerase activity. A series of telomerase positive 
cells (JFCF-6B, MCF7 and G361) were treated with Withaferin A, followed by TRAP 
assay analysis (A). Results of control and treated group were not statistically significant. 
(p > 0.05). Viability of MRC5 control and hTERT overexpressing cells was tested by 
MTT assay (B). Cells were incubated with Withaferin A for the 24 and 48h. Values 
were representative of three independent experiments and expressed as means. 
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Fig. 2- 9 DNA damage induction in Withafein A treated JFCF-1L cells. Cells were 
treated with 0.25 µg/ml of Withaferin A for 24h , then subjected to Comet assay and 
immunostaining of DNA damage marker protein ɣH2AX (A). Percent of DNA in tail 
and ɣH2AX positive cells were quantified as shown in B and C, respectively. Scale bar 
= 40 μm. 
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Fig. 2- 10 Withaferin A induced telomere dysfunction in JFCF-1L cell. Telomere 
dysfunction-induced foci (TIF) was measured by double immunostaining of TRF2 and 
ɣH2AX (A). Dysfunctional telomeres were recognized by Co-localization signals. 
Cells with at least 4 TIFs were counted as shown in B. Quantitation results were 
represented as mean ± SD of three independent experiments. Scale bar = 5 μm. 
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Fig. 2- 11 Western blotting analysis of telomere protection proteins. A decrease 
expression of TFR2 and POT1 was observed in JFF-1L(ALT) cells response to 
Withaferin A treatment (A). Quantitation results (B) were represented as mean ± SD of 
three independent experiments. 
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Fig. 2- 12 Western blotting of myc proteins (A) showed decrease level of expressin in 
JFCF-1L(ALT) cell in response of Withaferin A. MRN complex component proteins, 
myc downstream factors, were hence down-regulation by Withaferin-A in both mRNA 
(B) and protein (A and C) levels in JFCF-1L cell. Densitometric quantitation of 
representative blots are from at least three independent experiments (C).  
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Chapter 3 Noncoding regulation of drug induced DNA 
damage signaling and cellular senescence in ALT cells 
3.1 Introduction 
MicroRNAs (miRs) are a class of highly conserved small non-coding molecules 
(about 21-25 nucleotides long) that act as gene repressors by either causing their mRNA 
degradation or translational block. They are transcribed as pri-miRNAs and are 
subsequently processed into short hairpin structured molecules by Drosha, the double-
stranded RNA specific ribonuclease. Their involvement in diverse biological processes 
ranging from normal development to a variety of pathogenesis has been implicated.   
Hence, miR profiling has been considered to yield valuable outcomes not only in the 
understanding of regulation of basic biological phenomena, but also in disease, 
diagnosis, therapy and prognosis [140-142].  
Cancer is a complex disease. It is regulated by multifaceted network of signaling 
pathways driven by loss of activities of tumor suppressor proteins, gain of function of 
oncogenes and several epigenetic mechanisms [143-145]. Many miRs, including miR-21, 
miR-143, miR-145, miR-182 have been found as enriched in tumors and shown to 
possess oncogenic functions [146-148]. On the other hand, several others including 
miRNA-125b, miR-335-5p, and miR-34 family are down-regulated in several types of 
cancers [149-153]. Recently, it was shown that tumor suppressor protein p53 regulates 
miRNA expression and processing, and in turn is regulated by miRs. Restoration of 
p53-induced miRs was shown to cause suppression of tumor growth and metastasis in 
mouse models of cancer suggesting that there is a complex network of miR-p53 
interactions in the regulation of p53 activities, its effectors and regulators [154-156].  
Several other tumor suppressor pathways including pRB, PTEN, p16INK4A, BMI and 
p14ARF have been shown to be either regulated by miRs or involve them for their 
activities to implement control on cell proliferation [157-161]. In spite of imperative 
emerging evidence of the role of several miRs in cancer, the molecular targets and 
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mechanisms remain largely undefined. In addition, a number of miRs have also been 
characterized to possess both tumor suppressor and oncogenic functions [162] warranting 
molecular insights to their activities in context of cell physiology. 
Epigenetic control of cancer has been well established [145]. Several epigenetic 
drugs (DNA methyl-transferase and histone deacetylase inhibitors) that induce 
senescence in cancer cells have been in practice in conventional chemotherapy. 
However, their impact on the miRs and cancer progression remains largely unknown 
[163]. It was reported that miR-34 and miR-145 were silenced through DNA 
hypermethylation and were, hence, induced by 5Aza-dC treatment [164, 165]. In the 
present study, we used a bicistronic vector containing GFP reporter to arbitrarily induce 
miRs in human osteosarcoma (U2OS). Genomic integration of this vector was expected 
to induce transcription of sequences downstream to its integration sites. Based on the 
fact that more than 70% of the human genomic DNA constitutes protein-noncoding 
sequences, such random integration of the vector in genome was expected to induce a 
large variety of miRNAs (referred to as arbitrary miR library). Cells expressing such 
random library of miRs were subjected to 5-Aza-dC induced senescence for 3-5 days. 
Whereas untransduced controls showed senescence phenotype, some virus transduced 
cells escaped from 5-Aza-dC induced senescence (called loss of function) and was 
subjected to miR-array analysis with respect to the control (untransduced) cells. Out of 
several upregulated miRs, we aim to characterize the function of miR-335.  
3.2 Materials and methods 
3.2.1 Cell culture, transfections and drug treatments 
Osteosarcoma (U2OS and Saos-2), cervical carcinoma (HeLa), breast 
adenocarcinoma (MCF 7 and MDA-MB-231), lung carcinoma (A549 and H1299) and 
normal human fibroblasts (TIG and WI38) were purchased from Japanese Collection 
of Research Bioresources (JCRB, Japan) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% (v/v) 
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fetal bovine serum (Gibco BRL), and 1% (v/v) penicillin/streptomycin in the presence 
of 5% CO2 at 37
oC. Transfection was performed using X-tremeGENE 9 DNA 
transfection reagent (Roche Applied Sciences, Basel, Switzerland). Transfected cells 
were selected using blasticidin (10 μg/ml). Cells were treated with 20 μM of 5-Aza-
2’deoxycytidine (5-Aza-dC) (Sigma-Aldrich, St. Louis, MO, USA) for 48-96 h.  
3.2.2 Induction of arbitrary miR library and screening for miRNAs involved in escape 
from 5Aza-dC induced senescence 
To construct a retroviral vector pMXGbu, a short linker with 5’- 
gaattAGCGGAGGACAGTACTCCGATCGGAGGACAGTACTCCGTtcgac -3’ was 
inserted between EcoRI and SalI sites of pMXCRGb [166] by removing CMV-RFP 
cassette. Upon transduction, the upstream LTR of the vector drives GFP-Bsd fusion 
gene and the downstream LTR initiates random transcription. The transduced cells were 
selected in blasticidin (10 μg/ml) supplemented medium and were then subjected to 5-
Aza-dC (20 μM) for 3-5 days. The cells were subsequently harvested to prepare total 
RNA (RNeasy Plus Mini Kit (QIAGEN).  
3.2.3 Cloning of miR-335, expression plasmid  
pCXGb-miR-335: a primary miR-335 region was amplified from human genomic 
DNA by PCR using the following primers: 5’-
AACTCGAGTTCAGCCTTCATTGTTTAATCTTTACAACAGC-3’ and 5’- 
AAGATATCTGTATGGACATGAAGCTTTTACTTCAACATTAG-3’. The PCR 
product was digested with SalI and EcoRV and introduced into pCXGb as described 
earlier [167]. 
3.2.4 Senescence-associated β-galactosidase assay (SA-β-gal) 
SA-β-gal detection kit (Senescence Cells Histochemical Staining Kit, Sigma-
Aldrich) was used following manufacturer’s instructions. Cells showing blue staining 
were considered positive and counted under the microscope. Quantitation from three 
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independent experiments was performed.  
3.2.5 Flow cytometry 
Control and transfected cells were harvested by trypsin (0.25%). Cell pellets were 
washed with cold PBS and then added drop-wise to pre-chilled 70% ethanol. The fixed 
cells were centrifuged at 800×g for 5 min at 4°C, washed with cold PBS twice and 
then re-suspended in 0.25 ml PBS. The cells suspensions were treated with RNase A at 
37oC for 1 h followed by brief centrifugation to discard supernatant. Cells were re-
suspended in 200 µl of Cell Cycle Guava reagent (Millipore, Billerica, MA, USA), 
incubated for 30 min in dark, and analyzed by EasyCyte Guava cytometer (Millipore).  
The data were further analyzed using FlowJo software. 
3.2.6 Cell viability, proliferation and colony forming assay 
Equal number of control and transfected cells were plated in 96-well plates. After 
48 h of incubation at 37°C, 100 μl of MTT (Sigma-Aldrich) in PBS (5 mg/ml) was 
added to each well. After 4 h of incubation at 37 °C, the supernatant was discarded and 
the precipitate was dissolved with 100 ml of dimethylsulfoxide (DMSO). Plates were 
then read on a microplate reader (infinite M200 PRO, TECAN) at 570 nm.   
For cell proliferation assay, control and transfected cells were plated onto 12-well 
plates. Cells were harvested and counted in triplicates at the indicated time point using 
TC20TMAutomated Cell Counter (Bio-Rad, Hercules, CA, USA), with trypan blue 
exclusion to identify viable cells. Growth curves were generated for each cell line from 
three independent experiments.  
For long-term cell viability and proliferation, colony-forming assay was 
performed. 500 cells were plated in a 6-well plate and left to form colonies for the next 
10-15 days with a regular change of medium on every third day. Colonies were fixed 
with pre-chilled methanol/acetone (1/1, v/v) 10 min on ice, stained with 0.1% crystal 
violet solution, photographed and counted. 
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3.2.7 Cloning of pMIR-CARF-3’UTR plasmid 
CARF-3’untranslated region (UTR) was amplified by PCR (initial 10 min 
denaturation step at 98oC followed by 30 cycles of 98oC for 30s, 55oC for 30s and 72oC 
for 30s, with a final annealing step at 72oC for 10 min) using human genomic DNA 
with primers: 5’-GTTTAAACGTTTAAACTGTGTCCAAAATATCACTGC-3’ and 5’-
ACTAGTACTAGTCTAACAGACACGTTCAAC-3’. The PCR product was digested 
with Pme1 and Spe1, and then introduced into pMIR-REPORTTM Luciferase plasmid 
(Applied Biosystems, Forster, CA, USA) between these two sites. 
3.2.8 Luciferase reporter assay 
The pGL4-p53-3’UTR and pGL4-p21-3’UTR were generously provided by Dr. 
Chae-Ok Yun (Hanyang University, Seoul, South Korea). U2OS control and miR-335 
transfected cells were transfected with 1 μg of luciferase constructs (pGL4-p53-3’UTR, 
pGL4-p21-3’UTR or pMIR-CARF-3’UTR), 100 ng of control vector oligonucleotide 
(pRL-TK or pMIR-REPORTTM β-gal control plasmid) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). After 24 - 48 h, luciferase activity was measured 
using a dual luciferase reporter assay system and β-gal enzyme system (Promega, 
Madison, WI, USA) following the manufacturer’s protocol. Experiments were carried 
out in triplicate and repeated at least three times. 
3.2.9 RNA extraction and real-time qRT–PCR 
Total RNA was isolated from cells using the RNeasy mini kit (Qiagen, Standford 
Valencia, CA, USA). The concentration and purity of RNA were determined by 
ultraviolet spectrophotometry (A260/A280 >1.9) using NanoDrop ND-1000 
(Nanodrop Technologies, Wilmington, DE, USA).   
For CARF mRNA expression analyses, equal amount of RNA were used for 
reverse transcription following the protocol of QuantiTect Reverse Transcription Kit 
(Qiagen). The real-time qRT-PCR (50ºC for 2 min; 95ºC for 10 min, 40 cycles of 95ºC 
for 15 s, 60ºC for 1 min; and 72 ºC for 30 s) was performed using SYBR® Select Master 
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Mix (Applied Biosystems in triplicate on the Eco™ real time system (Illumina, San 
Diego, CA USA). The real-time qRT-PCR results were analyzed and expressed as 
relative expression of threshold cycle value, which was then converted to x-fold 
changes (2 − △△Ct) following manufacturer’s instructions. The primer sets included: 
p16INK4a (1), 5’-CCCAACGCACCGAATAGTTA-3’ (forward) and 5’-
ACCAGCGTGTCCAGGAAG-3’ (reverse); p16INK4a (2), 5’- 
GAAGGTCCCTCAGACATCCCC -3’ (forward) and 5’- 
CCCTGTAGGACCTTCGGTGAC -3’ (reverse); p16INK4a (3), 5’- 
CCCCTTGCCTGGAAAGATAC -3’ (forward) and 5’- 
AGCCCCTCCTCTTTCTTCCT -3’ (reverse); Rb, 5’- 
GGAAGCAACCCTCCTAAACC -3’ (forward) and 5’- 
TTTCTGCTTTTGCATTCGTG -3’ (reverse); CARF, 5’- 
TCAAAGTGACAGATGCTCCA -3’ (forward) and 5’- 
CGTTGAACTGTTTTCCTGCT -3’ (reverse); 18s, 5’- 
CAGGGTTCGATTCCGTAGAG -3’ (forward) and 5’- 
CCTCCAGTGGATCCTCGTTA -3’ (reverse). 
For miR-335 expression analysis, the corresponding miR-335 (Assay ID: 000546) 
and RNU6B (Assay ID: 001093) primers and TaqMan® MicroRNA assay was 
performed following the manufacturer's instructions (Applied Biosystems). RNU6B 
served as an endogenous control for normalization.  Real-time qRT-PCR reaction was 
conducted at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 65°C for 1 
min.  
3.2.10 Western blotting 
Cells were harvested using RIPA buffer (Thermo Scientific, Waltham, MA, USA) 
supplemented with a protease inhibitor cocktail (Roche). The protein concentrations 
were determined by using the Pierce BCA Protein Assay Kit (Thermo Scientific). 
Western blotting was performed by using following antibodies: anti-p16 (C-20), anti-
p21 (C-19), anti-p53 (DO-1), anti-MDM2 (HDM2-232), anti-Cdk4 (C-22), anti-E2F 
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(MH5), anti-GFP (B-2) (Santa Cruz, CA, USA), anti-Phospho-Rb (Ser780), anti-Rb 
(4H1) (Cell Signaling, Danvers, MA, USA) and anti-CARF (FLA-10)[168]. Anti--actin 
antibody (AC-15) (Abcam, Cambridge, MA, USA) was used as an internal loading 
control. All the experiments were performed in triplicate at least three times. 
3.2.11 Immunostaining 
Cells were cultured on a glass coverslip placed in a 12-well culture dish.  For 
immunostaining, cells were washed (cold PBS), fixed (pre-chilled methanol/acetone 
(1:1) mixture for 10 min), permeabilized (0.5% Triton X-100 in PBS for 10 min), 
blocked (0.2% BSA/PBS for 1 h) and were then incubated with specific antibody (as 
described above) for overnight at 4°C. They were incubated with Alexa-594-conjugated 
goat anti-mouse or anti-rabbit (Molecular Probes, Invitrogen) secondary antibodies 
after washings (thrice) with 0.2% Triton X-100 in PBS. Counterstaining was performed 
with Hoechst 33342 (Sigma) for 10 min in dark following by extensive washings with 
0.2% Triton X-100 in PBS and observations under a Carl Zeiss microscope (Axiovert 
200 M, Tokyo, Japan) . 
3.2.12 In vivo tumor formation assay                                
Balb/c nude mice (4 weeks old, female) were provided by the Institute of 
Laboratory Animal Science of Peking Union Medical College, China. Cells (A549 and 
A549-miR335 derivatives) were injected into the nude mice subcutaneously (5 x 106 
suspended in 0.2 ml of growth medium). Tumor formation and mice health (body 
weight) was monitored every alternate day. The experiment was repeated twice, using 
4 mice in each group. Volume of the subcutaneous tumors was calculated as V=L x 
W2/2, where L was length and W was the width of the tumor, respectively. Protocols 
for animal experiments were approved by the Animal Care and Use Committee, 
Institute of Laboratory Animal Science of Peking Union Medical College, China 
(ILAS-PG-2014-018). 
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3.2.13 miRNA array 
Control (untransduced and untreated) and virus transduced and 5-Aza-dC (20 μM) 
treated cells (pooled colonies) that escaped senescence were harvested. For miRNA 
microarray, small RNAs (less than 200 nt including precursor and mature miRNAs) 
were extracted using mirVana miRNA isolation kit (Ambion, Austin, TX, USA) 
following the manufacturer’s protocol. Purified RNA was labeled with Cy3 or Cy5 
using the mirVana miRNA labeling kit (Ambion). Labeled RNA was hybridized with 
oligonucleotides against human miRs arrayed on slides (Hokkaido-System Science, 
Japan), and detected by a scanner (Agilent Technologies, Santa Clara, CA, USA). 
3.2.14 Statistical analysis 
All experiments were carried out in triplicates, and data were expressed as mean 
± standard deviation (SD). Two-tailed Student’s t-test or nonparametric ManneWhitney 
U-test, whichever was applicable, was used to determine the degree of significance 
between the control and experimental sample. Statistical significance was defined as p-
value ≤ 0.05. 
3.3 Results and discussion 
3.3.1 Identification of miR-335 in loss-of-function screening of miRs involved in 
escape of 5-Aza-dC induced senescence 
A retroviral vector constituting two long terminal repeat (LTR) promoters on the 
5’ and 3’ ends of the gene for GFP was generated in a way that the random integration 
of this vector in the genome would result into (i) expression of GFP; detected by green 
fluorescence and (ii) its integration-dependent arbitrary manipulation of the host cell 
genome. The latter may yield loss of function phenotype due to altered expression of 
either proteins or their noncoding regulators miRs. We coupled this system with 
induction of senescence in human cancer cells (U2OS) by demethylating drug, 5-Aza-
dC. The cells that escaped senescence were selected by their propagation and were 
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subjected to microRNA array with respect to the untreated control cells (Fig. 3-1). We 
found that several miRNAs (miR-101, miR-143, miR-145, miR-335, miR-451, miR-
545 and miR-558) were upregulated in vector-transduced cells that showed resistance 
to 5-Aza-dC induced senescence (Fig. 3-1). Of note, two of these miRs (miR-145 and 
miR-335) have been reported to undergo hypermethylation-mediated silencing in a 
large variety of cancers [164, 169] and hence their upregulation by 5-Aza-dC induced 
demethylation was justified. Furthermore, our data suggested that these miRs are 
involved in regulation of induction of cellular senescence, proliferation and drug 
response of cells. We aimed to characterize such functions and targets of miR-335 in 
this study.   
3.3.2 miR-335 compromises 5-Aza-dC induced senescence by retard of cell cycle 
progression 
An expression plasmid encoding primary miR-335 was transfected into U2OS 
cells. Treatment of control or miR-335 derivatives with 5-Aza-dC and detection of 
senescent cells by senescence associated -gal staining revealed that miR-335 
compromised induction of senescence. There was about 50% reduction in the SA--gal 
positive cells in miR-335 derivatives (Fig. 3-2A). Cell viability analysis also showed 
resistance of miR-335 derivatives to 5-Aza-dC at all doses tested (Fig. 3-2B) suggesting 
that the upregulation of miR-335 was involved in the escape of cells from 5-Aza-dC 
induced senescence/growth arrest. We further examined if induction of senescence 
involved downregulation of miR-335 expression. 5-Aza-dC treated cells were collected 
and subjected to miR-335 expression analysis. We found that miR-335 was 
downregulated in these cells (Fig. 3-2C), endorsing the role of upregulated miR-335 in 
escape of cells from senescence. Taken together, these data suggested that miR-335 is 
downregulated in cells that showed senescence upon 5-Aza-dC treatment, and that 
overexpression of miR-335 suppressed the senescent phenotype.  
In order to clarify the mechanism of this phenomenon, we considered two 
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possibilities: (i) Based on the fact that incorporation of 5-Aza-dC takes place during 
replication and DNA synthesis, we hypothesized that miR-335 might cause growth 
arrest of cells leading to the situation that 5-Aza-dC was not incorporated into the 
genome, and (ii) miR-335 may target genes that are essential for 5-Aza-dC induced 
growth arrest. We tested the possibility (i) by analyzing the growth and cell cycle 
characteristics in control and miR-335 derivatives. As shown in Figs. 3-3, the latter 
were retarded in their growth (A) and showed lower viability (B) in short term as well 
as long term colony-formation assays (C). Cell cycle analysis revealed increase in 
number of cells at G0/G1, G2/M and decrease in S phase (Fig. 3-4A). These data 
suggested that miR-335 caused growth arrest of cells that may have contributed, at least 
in part, to the escape of cells to 5-Aza-dC induced senescence as hypothesized above. 
Growth arrest function of miR-335 was also confirmed by in vivo subcutaneous 
xenografts of control and miR-335 derivatives of A549 cells in nude mice (Fig. 3-4B). 
We found that the tumor growth of miR-335 derivatives was suppressed as compared 
to the control cells. Physiological relevance of miR-335 was determined by its 
expression analysis in normal and cancer cells.  Consistent with its role in growth 
arrest, miR-335 expression was high in normal fibroblasts as compared to a variety of 
cancer cells (Fig. 3-4C). Furthermore, consistent with induction of growth arrest and 
tumor suppressor activity of miR-335, the miR-335 overexpressing cells showed 
upregulation of p21WAF1 and downregulation of CDK4 (Figs. 3-5A and 5B).  
3.3.3 Effect of miR-335 on p16INK4A and pRB resulting in compromised 5-Aza-dC-
induced senescence 
We next considered the second possibility that the miR-335 may target essential 
genes involved in 5-Aza-dC induced growth arrest. In U2OS cells, p16INK4A (cyclin-
dependent kinase inhibitor and tumor suppressor) is known to undergo silencing by 
hyper-methylation of its promoter [170]. As expected, 5-Aza-dC treated cells showed 
induction of p16INK4A (Figs. 3-6A and 6B). Of note, we found that miR-335 transfected 
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cells showed downregulation of 5-Aza-dC induced p16INK4A protein expression 
suggesting that miR-335 may target p16INK4A directly or indirectly and hence may 
account for escape of 5-Aza-dC induced senescence in miR-335 transfected cells. In 
order to confirm this, we determined the expression of p16INK4A in control and miRNA-
transfected cells by qPCR using three sets of primers and, surprisingly, found increase 
in p16INK4A transcript in 5Aza-dC treated control as well as miR-335 overexpressing 
cells (Fig. 3-6C). These data suggested that decrease in p16INK4A protein observed in 
miR-335 overexpressing cells was not due to direct targeting of p16INK4A mRNA by 
miR-335.  
p16INK4A is an established inhibitor of cyclin D-CDK4 complex. The latter 
phosphorylates retinoblastoma protein resulting in dissociation of pRB-E2F1 complex 
and cell cycle progression that requires free E2F1. Accordingly, targeting of p16INK4A 
by miR-335 was expected to result in activated cyclin D-CDK4 complex resulting in 
increased level of phosphorylated pRB in miR335 derivatives. We examined the levels 
of pRB and phospho-pRB and found, contrary to the expected, decrease in phospho-
pRB in miR-335 derivatives (As shown in Fig. 3-7A). Western blotting with pRb and 
phospho-pRB specific antibodies also confirmed their downregulation in miR-335 
derivatives (Fig. 3-7B). qPCR analysis also revealed decrease in pRB transcript in miR-
335 overexpressing cells (Fig. 3-7C), endorsing that miR-335 targets pRB. In light of 
this data, decrease in phosphorylated-pRB was accounted for cell cycle retardation, and 
hence escape of cells from 5-Aza-dC induced senescence. Another study also showed 
that during differentiation of mouse embryonic stem cells, miR-335 is upregulated and 
causes down regulation of Oct4-pRB axis and pRB dephosphorylation [158]. In this 
report, miR-335 was shown to target pRB directly and specifically targeting a 
conserved sequence motif in its 3' un-translated region [157]. However, it was shown to 
result in consequential activation of p53 tumor suppressor resulting in inhibition of cell 
proliferation and transformation. Taken together with our findings, it emerged that miR-
335 is an important miR that controls cell proliferation by balancing the activities of 
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the pRB and p53 tumor suppressor pathways.   
3.3.4 miR-335 targets CARF and compromises 5-Aza-dC induced senescence  
In light of the information that miR-335 targets pRB and activates p53 [157], we 
examined the level of p53 in control and miR-335 derivatives. As shown in Fig. 4, we 
found decrease in p53 protein level in miR-335 derivatives (Figs. 3-8A and 8B, Fig. 3-
9A). We next determined the mechanism of such decrease and its impact in escape of 
cells from 5-Aza-dC induced senescence. Since p53 is degraded by its antagonist 
HDM2, we examined its level of expression in control and miR-335 derivatives. As 
shown in Figs. 3-8 and 3-9, miR-335 derivatives showed higher level of HDM2 by 
Western blotting (Figs. 3-8A and 8C) as well as immunostaining (Fig. 3-9B) suggesting 
that miR-335 may target an upstream inhibitor of HDM2, leading to its increased levels 
that in turn caused decrease of p53 in miR-335 derivatives. 
CARF (Collaborator of ARF), a protein that poses two-way control on cell 
proliferation, has been shown to be an upstream regulator of p53 [171-173]. Whereas its 
upregulation occurred during replicative and premature senescence, its super-high level 
was shown to be associated with tumorigenesis and malignant transformation of cancer 
cells[174]. It was shown to act as a transcriptional repressor of HDM2 (an antagonist of 
p53) [175]. In view of above findings on miR-335, we examined CARF-p53-HDM2-p21 
axis in miR-335 cells. As shown in Fig. 3-10, these cells showed down-regulation of 
CARF at protein (A and C) as well as mRNA (B) levels implying that miR-335 targets 
CARF, and may account for increased level of HDM2 and decreased level of p53 (Figs. 
3-8 and 3-9).   
In order to finally resolve whether miR-335 directly targets CARF, p53 and 
p21WAF1, we performed reporter assays using 3’UTR regions of these genes. As shown 
in Fig. 3-11A, we found that CARF, but not p53 and p21WAF1, was the target of miR-
335. As shown in Figs. 3-5A and 5B, contrary to the decreased level of expression of 
p53, its downstream effector and major regulator of growth arrest, p21WAF1 showed 
increase in miR-335 derivative cells. This was in line with our recent findings that high 
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level of CARF expression acts as a repressor of p21WAF1 [176] and hence targeting of 
CARF by miR-335 accounted for increase in p21WAF1 and growth arrest of miR-335 
derivatives in spite of knockdown of p16INK4A and pRB (Fig. 3-6 and 3-7). p21WAF1-
promoter luciferase reporter assays in control and miR-335 derivatives also showed 
increase in p21WAF1 reporter activity in miR-335 overexpressing derivatives (Fig. 3-
11C). Furthermore, we determined that this increase in p21WAF1 was independent to that 
of p53 by using p53-/- cells (Saos-2). As shown in Fig. 3-11B, miR-335 derivatives 
showed decrease in CARF and increase in p21WAF1 suggesting that miR-335 targets 
CARF and caused increase in p21WAF1 independent to that of p53. In order to resolve if 
miR-335 is involved in senescence induced by other drugs, we subjected cells to 
retinoic acid- and doxorubicin-induced senescence. As shown, CARF increased and 
miR-335 decreased in drug-treated cells that caused growth arrest (Fig. 3-11D). 
CARF is an essential cell proliferation-regulatory protein that is upregulated 
during replicative and stress-induced senescence. Suppression of CARF induced 
aneuploidy, DNA damage and mitotic catastrophe resulting in apoptosis endorsing that 
it is an essential for cell survival [172]. It has been shown to bind to multiple proteins, 
p14ARF, p53 and HDM2 of ARF-p53-p21 tumor suppressor axis and control cancer cell 
proliferation in two directions in a dose dependent way [171, 174, 177]. It was shown that 
while moderate level of CARF overexpression induced senescence, its very high level 
resulted in increased cell proliferation. Hence, CARF was demonstrated to determine 
the proliferative fate of cancer cells towards growth arrest or pro-proliferative and 
malignant phenotypes by feedback and feed-forward regulatory loops of CARF-ARF-
p53-HDM2-p21WAF1 axis. Molecular mechanism(s) of such dual regulation and how 
CARF is regulated in normal and cancer cells have not been fully understood. It was 
shown that CARF is involved in drug-induced senescence [171] and hence its knockdown 
by miR-335, induced by 5-Aza-dC mediated demethylation accounts, at least in part, 
for escape of cells from 5-Aza-dC induced senescence.  
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3.3.5 Wi-A causes induction of miR-335, resulting in down-regulation of CARF in TEP 
cells  
In light of the mechnism we presented in Fig. 3-12B, miR-335 caused cell cycle 
retard through regulation of CARF. In Chapter 2, results showed that Wi-A treatment 
led to cell growth suppression, and finally induced apoptosis. Such similar phenotype 
drove us to suspect whether miR-335 was involved in Wi-A-mediated physiological 
activities. Hence, we conducted qPCR analysis and found miR-335 was only up-
regulated by Wi-A treatment in JFCF-6B TEP cell (Fig. 3-13A). We examined the 
expression level of CARF. As we expected, Wi-A treatment decreased CARF 
expression in TEP cells, while Wi-A treated ALT cells showed no difference with 
respect to the control group (Fig. 3-13B). Western blotting for p21 and CDK6 revealed 
up-regulation of p21 and down-regulation of CDK6 in TEP cells by Wi-A treatment, 
whereas variation trend in ALT cells was relatively moderate (Fig. 3-13B). Of note, we 
found the CARF expression level in ALT cells was less than TEP cells. Such a lower 
expression of CARF might make ALT cells insensitive to miR-335-mediated growth 
suppression. Considering the fact that ALT cells showed more DNA damage than TEP 
cells during Wi-A treatment (Fig. 2-10 and 2-9), it may be possible Wi-A-induced 
growth retardation gains the repairing time of DNA damage for JFCF-6B TEP cells, 
which blunts the induction of apoptosis as shown in Chapter 2. 
3.4 Summary 
We demonstrated that CARF is a new target of miR-335 that mediates its tumor 
suppressor function. Pleotropic effects of miR-335 demonstrated in the present study 
and others (as discussed above) may be due to, at least in part, its control on CARF 
expression that has been shown to impose a dose dependent and contrasting effect on 
proliferation and malignant transformation of cancer cells. We demonstrated that 
targeting of CARF by miR-335 resulted in upregulation of p21WAF1, downregulation of 
cyclin-CDK activity (Fig. 3-5). Furthermore, CARF has also been shown to cause 
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upregulation of p16INK4A 31. Hence CARF-targeting by miR-335 also accounted for 
downregulation of p16INK4A protein (Fig. 3-6A and 6B) in spite of the fact that p16INK4A 
mRNA was increased in miR-335 and 5-Aza-dC treated cells. These data suggested 
miR-335 effects (such as, decrease in p16INK4A protein, increase in HDM2 and p21WAF1) 
and outcomes such as growth arrest are determined predominantly by CARF-targeting.  
Taken together, CARF emerged as a new strong target of miR-335, demanding 
further studies for its potential as an important noncoding tumor suppressor in cancer 
therapeutics.  
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Fig. 3- 1 Identification of miR-335. Strategy for induction of miR library in human 
cancer cells and loss-of-function screening is described (A). The cells infected with 
bicistronic vector constituting of two promoters and GFP were treated with 5-Aza-dC.  
Whereas control uninfected cells showed induction of senescence, colonies emerged in 
the virus harboring cells. These colonies were expanded and subjected to miR-array 
analysis with respect to the uninfected control cells. miR array analysis resulted in 
identification of miR-335 as one of the upregulated miR in cells that escaped 5-Aza-dC 
induced senescence.  
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Fig. 3- 2 Cells overexpressing miR-335 showed resistance to 5-Aza-dC induced 
senescence as examined by senescence associated -gal staining (A) as well as cell 
viability assays (B). Cells undergoing 5-Aza-dC induced senescence showed down-
regulation of miR-335 (C). 
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Fig. 3- 3 Growth curve of control and miR-335 overexpressing cells showed slower 
growth of the latter (A). Short and long term survival by viability analysis (B) and 
colony forming assay (C) showed about 30% and 50% reduction, respectively. 
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Fig. 3- 4 Cell cycle analysis showed increase in number of cells at G0/G1, and decrease 
in S phase (A). miR-335 overexpressing cells, in subcutaneous xenografts in nude mice, 
showed low tumor forming capacity as compared to the control cells. Body weight of 
the mice during the course of experiment showed no difference (B). Expression analysis 
of miR-335 in human normal and cancer cells showed its higher level of expression in 
normal cells (C). 
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Fig. 3-5 Western blotting (A) and immunostaining (B) showed miR-335 overexpressing 
cells possessed higher level of expression of p21WAF1, and low level of expression of 
CDK4. Scale bar = 30 μm. 
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Fig. 3- 6 Immunostaining (A) and Western blotting (B) of control, miR-335-transfected 
cells treated with 5Aza-dC showed that the latter caused increase in expression of 
p16INK4A and miR-335 compromised p16INK4A increase at the protein (A and B), but not 
mRNA level (C). miR-335 transfected and 5Aza-dC treated cells showed increase in 
p16INK4A transcript that was confirmed by three sets of primers. Scale bar = 50 μm. 
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Fig. 3- 7 Immunostaining (A) and Western blotting (B) for pRB in control and miR-
335 cells revealed low level of expression of pRB and pRBphospho in the latter. miR-335 
transfected cells showed lower level of pRB transcript (C). Scale bar = 20 μm.  
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Fig. 3- 8 Western blotting of control and miR-335 cells treated with 5-Aza-dC showed 
low level of p53 in the latter, 5-Aza-dC increased the p53 expression, HDM2 showed 
reverse expression as p53 (A). Quantitation of Western blotting data obtained from 
three independent experiments and the statistical significances are shown (B and C). 
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Fig. 3- 9 Imumostaining of control and miR-335 cells treated with 5-Aza-dC showed 
low level of p53 in the latter, 5-Aza-dC increased the p53 expression (A), HDM2 
showed reverse expression as p53 (B).  
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Fig. 3- 10 Western blotting (A), qRT-PCR (B) and immunostaining (C) for CARF 
showed decreased level of expression in miR-335 overexpressing cells. 
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Fig. 3- 11 3’UTR reporter assay for CARF, p53 and p21 in control and miR-335 
overexpressing cells showed that miR-335 targets CARF (A). Increase in p21WAF1 
occurred in p53-/- cells and was hence independent to that of p53 (B). p21WAF1 promoter 
reporter assay in control and miR-335 transfected cells showed upregulation of p21 (C). 
Cells undergoing growth arrest by retinoic acid (ATRA) and doxorubicin (Dox) showed 
decrease in miR-335 and increase in CARF expression; 5Aza-dC was used as a control 
for comparison (D). 
 
 
 
C 
0
20
40
60
80
100
120
140
R
e
la
ti
v
e
 l
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
Control miR-335
** ≤ 0.01 
vs Control 
** 
A549 Saos-2 
ß-actin 
GFP 
p21 
p53 
CARF 
0
50
100
150
200
250
 Control miR-335
R
e
la
ti
v
e
 W
W
P
 l
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
*** 
*** ≤ 0.001 
vs Control 
0
0.5
1
1.5
2
2.5
3
3.5
Control 5-Aza-dC ATRA Dox
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 l
e
v
e
l
miR-335
CARF mRNA
** ** 
** 
** 
** ≤ 0.01 
*** ≤ 0.001 
vs Control 
*** 
*** 
B A 
D 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3- 12 miR-335 transfected cells showed low expression level of E2F-5 than control 
cells (A). Schematic presentation of miR-335 targets as resolved in this study. Dominant 
pathways are shown by solid lines. Upregulation and downregulation of proteins are 
shown by upward and downward arrows (B).   
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Fig. 3- 13 Telomerase positive JFCF-6B cell showed higher miR-335 expression in 
response to Wi-A treatment (A). Hence, in JFCF-6B cell, Wi-A treatment led to down-
regulated of CARF and CDK6, up-regulated of p21, whereas JFCF-1L was relatively 
less affected because of low level of CARF expression (B). 
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Chapter 4 Conclusions and future research 
Each of the ~103 human cells receives tens of thousands of DNA lesions per day. 
To counter this threat, life has evolved several systems to mediate its repair. However, 
if the cells are not repair or repair incorrectly, they lead to mutations or wide-scale 
genome aberrations that results in tumorigenesis. Today, Cancer has been on the rise 
since the average human lifespan has increased so dramatically over the last century. 
The development of industrialization and unhealthy lifestyles also increase the 
incidence of this disease. Although advancements in diagnostic and therapeutic 
technologies have improved cancer survival statistics, 75% of the world population live 
in developing country and have poor access to the advanced remedies. Natural plant 
therapies, like Ashwagandha, hence become an alternative choice for treatment. We 
aim to study anticancer activity of Withaferin A (extract from Ashugandha leaf) in 
aspects of telomere maintenance and mircoRNA regulation. 
4.1 Conclusions 
In this thesis, we used isogenic cells with or without telomerase and found that: 
1. Wi-A caused stronger cytotoxity to ALT cells. The G2/M arrest and apoptosis 
resulting from Wi-A exposure was specific to ALT cells.  
2. Treatment with Wi-A decreased in the number of ALT-associated 
promyelocytic leukemia (PML) nuclear bodies (APBs) (a universal 
characterization of ALT), whereas telomerase activity was unaffected.  
3. ALT cells treated with Wi-A exhibited severe telomere dysfunction and 
upregulation of DNA damage response.  
4. Molecular analysis revealed that treatment with Wi-A lead to Myc- mediated 
transcriptional suppression of MRN complex, which is essential for ALT 
mechanism and cell survival.  
In the meanwhile, we recruited arbitrary manipulation of genome and escape from 
5-Aza-2'-deoxycytidine (5-Aza-dC) induced senescence as a cell based loss-of-function 
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screening system. Cells that escaped 5-Aza-dC induced senescence were recovered and 
subjected to miR-microarray analysis with respect to the untreated control. We 
identified that: 
1. miR-335 as one of the upregulated miRs in the cells that escaped 5-Aza-dC 
induced senescence. 
2. miR-335 overexpression in a variety of human cancer cells with either 
telomerase or ALT mechanism causes growth arrest and hence inhibited 
incorporation of 5-Aza-dC enabling cells to escape induction of senescence. 
3. miR-335 targets multiple proteins including p16INK4A, pRB and CARF 
(Collaborator of ARF) and causes growth arrest of cancer cells by complex 
interactions of its gene targets.  
4. miR-335 expression is increased by Wi-A treatment in telomerase cells, 
inducing CARF mediated cellular growth arrest. 
Collectively, this study provide a new strategy for the development of Wi-A based 
drug screening and designing in the future. 
4.2 Future work 
1. In spite of the obstacle that ALT cells don’t form xenograft tumor, Wi-A effect on 
telomerase/ALT or miRNA-335 should be confirmed by in vivo or ex vivo study 
2. The top Wi-A targeted molecule(s) in cancer cells needs to be identified. This will 
ultimately help to understand the underlying mechnism. 
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